The pharma-funded system at the FDA is becoming more prevalent and, because of the funding structure now in place, will not be easy to unpick. With such a large proportion of the drug regulation budget deriving directly from drug makers, and more input from drug makers at every stage in the process, the divide between the FDA and drug makers is rapidly shrinking.